Hanchor Bio-KY (漢康生技; 6995 TW) announced on May 26, 2026, the successful completion of the bookbuilding and bookrunning processes for its initial public offering (IPO) on the Taiwan Innovation Board (TIB). Driven by high subscription demand from both domestic and international institutional funds, the final IPO offer price has been settled at NT$120 per share, with its formal listing scheduled for May 29, 2026. A primary focal point for global markets is Hanchor Bio’s success in attracting a strategic cornerstone investment from OrbiMed, the world's premier healthcare and life sciences dedicated investment firm.
Strategic Validation via OrbiMed: OrbiMed, which commands an asset-under-management (AUM) footprint exceeding US$17 billion, maintains an institutional investment mandate that spans biopharmaceuticals, medical devices, diagnostics, and digital health globally. Hanchor Bio noted that OrbiMed’s direct equity investment in a Taiwanese novel drug developer represents a rare and significant validation, demonstrating international capital market confidence in Hanchor Bio’s proprietary FBDB™ fusion protein platform and its clinical oncology pipeline.
Controlled Float and Low-Dilution Share Strategy: The company adopted a low-proportion share release strategy for its IPO, with the newly listed shares representing approximately 6% of the company's total paid-in capital. Backed by an already robust corporate treasury, management selected this structure to optimize capital raising efficiency and defend existing shareholder equity against over-dilution, while introducing long-term, stable institutional capital to ensure post-listing share price stability.
Financial Runway and Patent Cliff Opportunities: Following the close of this funding round, Hanchor Bio’s consolidated liquid cash reserves and available banking credit facilities will total nearly US$140 million (approximately NT$4.5 billion). This capital runway is fully structured to fund multi-year global Phase 2 clinical programs, process chemistry optimizations (CMC), and international out-licensing initiatives.
Executive Commentary: Hanchor Bio Chairman and CEO Dr. Scott Liu emphasized that the global pharmaceutical sector is approaching an unprecedented patent cliff period over the coming fiscal cycles, during which blockbuster immuno-oncology therapies, including Keytruda, will lose patent exclusivity. International big-pharma corporations are actively scouring the global landscape for external licensing opportunities and next-generation technology platforms. As Hanchor Bio continues to advance its clinical validation data, the company is optimally positioned to unlock significant global out-licensing and commercial co-development value.
Resource:IPO超額認購 漢康-KY引資國際醫療基金OrbiMed策略入股
